Bayer Group Key Data

 

 

Q3 2016

Q3 2017

 

Change

 

9M 2016

9M 2017

 

Change

 

Full Year 2016

 

 

€ million

€ million

 

%

 

€ million

€ million

 

%

 

€ million

2016 figures restated

1

For definition see Annual Report 2016, Chapter “Alternative Performance Measures Used by the Bayer Group.”

2

Employees calculated as full-time equivalents (FTEs)

Sales

 

8,258

8,025

 

−2.8

 

26,120

26,419

 

+1.1

 

34,943

Change (adjusted for currency and portfolio effects)1

 

 

 

 

+1.2

 

 

 

 

+1.1

 

+4.7%

Change in sales1

 

 

 

 

 

 

 

 

 

 

 

 

Volume

 

+2.7%

+2.2%

 

 

 

+4.0%

+1.3%

 

 

 

+3.9%

Price

 

+1.8%

−1.0%

 

 

 

+1.0%

−0.2%

 

 

 

+0.8%

Currency

 

−1.2%

−4.1%

 

 

 

−2.9%

−0.1%

 

 

 

−2.2%

Portfolio

 

0.0%

+0.1%

 

 

 

0.0%

+0.1%

 

 

 

0.0%

EBITDA1

 

1,996

1,969

 

−1.4

 

7,260

7,103

 

−2.2

 

8,801

Special items1

 

(122)

(235)

 

 

 

(252)

(402)

 

 

 

(517)

EBITDA before special items1

 

2,118

2,204

 

+4.1

 

7,512

7,505

 

−0.1

 

9,318

EBITDA margin before special items1

 

25.6%

27.5%

 

 

 

28.8%

28.4%

 

 

 

26.7%

EBIT1

 

1,397

1,388

 

−0.6

 

5,152

5,278

 

+2.4

 

5,738

Special items1

 

(125)

(249)

 

 

 

(501)

(595)

 

 

 

(1,088)

EBIT before special items1

 

1,522

1,637

 

+7.6

 

5,653

5,873

 

+3.9

 

6,826

Financial result

 

(233)

(403)

 

−73.0

 

(741)

(1,068)

 

−44.1

 

(965)

Net income (from continuing and discontinued operations)

 

1,187

3,881

 

.

 

4,078

7,188

 

+76.3

 

4,531

Earnings per share (from continuing and discontinued operations) (€)1

 

1.43

4.45

 

.

 

4.93

8.24

 

+67.1

 

5.44

Core earnings per share
(from continuing operations) (€)1

 

1.53

1.47

 

−3.9

 

5.58

5.33

 

−4.5

 

6.67

Net cash provided by operating activities
(from continuing and discontinued operations)

 

3,053

2,711

 

−11.2

 

6,357

5,865

 

−7.7

 

9,089

Cash outflows for capital expenditures

 

656

557

 

−15.1

 

1,608

1,448

 

−10.0

 

2,163

Research and development expenses

 

1,055

1,079

 

+2.3

 

3,160

3,270

 

+3.5

 

4,405

Depreciation, amortization and impairments

 

599

581

 

−3.0

 

2,108

1,825

 

−13.4

 

3,063

Number of employees at end of period2

 

99,517

99,845

 

+0.3

 

99,517

99,845

 

+0.3

 

99,592

Personnel expenses (including pension expenses)

 

2,333

2,300

 

−1.4

 

7,002

7,281

 

+4.0

 

9,459